A4138-10mg | Tofacitinib (CP-690550,Tasocitinib) [477600-75-2] Biotrend

Background

Tofacitinib, also named CP-690550 orTasocitinib, is a novel oral Janus kinase inhibitor which is being used as a targeted immune-modulator. It primarily inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Inhibition of JAK1 and JAK3 by tofacitinib blocks signaling for several cytokines, including interleukins 2, 4, 7, 9, 15, and 21. These cytokines are integral to lymphocyte activation, function, and proliferation. Tofacitinib is also an inhibitor of STAT molecules. Recent efforts to investigate the mechanism of action have shown that tofacitinib interacts with multiple JAKs and presumably other kinases

References

Roy Fleischmann, Joel Kremer, John Cush, Hendrik Schulze-Koops, Carol A. Connell, John D. Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, and Keith S. Kanik. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med 2012; 367:495-507

William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Chinyu Su, Samantha Rousell, Wojciech Niezychowski. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. N Engl J Med 2012; 367:616-624.

Keisuke Maeshima, Kunihiro Yamaoka, Satoshi Kubo, Kazuhisa Nakano, Shigeru Iwata, Kazuyoshi Saito, Masanobu Ohishi, Hisaaki Miyahara, Shinya Tanaka, Koji Ishii, Hironobu Yoshimatsu, Yoshiya Tanaka. The JAK Inhibitor Tofacitinib Regulates Synovitis Through Inhibition of Interferon- and Interleukin-17 Production by Human CD4 T Cells. Arthritis & Rheumatism. 2012. 64(6): 1790–1798.

Product Citation

1. Malle L, Patel RS, et al. "Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells." Nature 2023 Feb 22 PMID: 36813963
2. M S Jessica E Neil, Jon D Lenn, et al. "A new ex vivo skin model for mechanistic understanding of putative anti-inflammatory topical therapeutics." Int J Pharm. 2022 Apr 5;617:121610. PMID: 35202723
3.Liu S, Verma M, et al. "Steroid Resistance of Airway Type 2 Innate Lymphoid Cells (ILC2s) from Severe Asthma: The Role of Thymic Stromal cell Lymphopoietin (TSLP)." J Allergy Clin Immunol. 2017 Apr 19. pii: S0091-6749(17)30660-7. PMID:28433687

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	312.37
Cas No.	477600-75-2
Formula	C₁₆H₂₀N₆O
Solubility	insoluble in EtOH; insoluble in H2O; ≥15.6 mg/mL in DMSO
Chemical Name	3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
SDF	Download SDF
Canonical SMILES	CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:
Cell lines	Human T cells and human myelomonocytic cell line HUO3
Preparation method	The solubility of this compound in DMSO is > 15.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition	0 ~ 4000 nM; 4 days
Applications	In human T cell blasts induced by IL-2, CP-690550 inhibited cell proliferation with an IC50 value of 11 nM. In human myelomonocytic HUO3 cells induced by GM-CSF, CP-690550 inhibited cell proliferation with an IC50 value of 324 nM.
Animal experiment [1]:
Animal models	Heterotopic heart transplantation mouse model
Dosage form	0 ~ 136 ng/mL; osmotic minipump infusion
Applications	In a heterotopic heart transplantation mouse model, CP-690550 dose-dependently increased survival of transplanted hearts. Mice received CP-690550 at the concentration of ~ 60 ng/mL maintained their grafts for > 28 days.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1]. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003 Oct 31;302(5646):875-8.